Chartwell Investment Partners LLC Has $1.28 Million Stake in Myokardia Inc (MYOK)

Chartwell Investment Partners LLC decreased its holdings in shares of Myokardia Inc (NASDAQ:MYOK) by 6.8% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 30,408 shares of the biotechnology company’s stock after selling 2,211 shares during the quarter. Chartwell Investment Partners LLC’s holdings in Myokardia were worth $1,280,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Wells Fargo & Company MN grew its stake in shares of Myokardia by 2.5% during the second quarter. Wells Fargo & Company MN now owns 18,539 shares of the biotechnology company’s stock valued at $243,000 after buying an additional 455 shares during the last quarter. American International Group Inc. grew its stake in shares of Myokardia by 18.8% during the third quarter. American International Group Inc. now owns 12,735 shares of the biotechnology company’s stock valued at $546,000 after buying an additional 2,018 shares during the last quarter. Rhumbline Advisers grew its stake in shares of Myokardia by 12.4% during the third quarter. Rhumbline Advisers now owns 20,788 shares of the biotechnology company’s stock valued at $891,000 after buying an additional 2,299 shares during the last quarter. Nationwide Fund Advisors grew its stake in shares of Myokardia by 36.3% during the second quarter. Nationwide Fund Advisors now owns 9,729 shares of the biotechnology company’s stock valued at $127,000 after buying an additional 2,591 shares during the last quarter. Finally, Strs Ohio grew its stake in shares of Myokardia by 23.6% during the fourth quarter. Strs Ohio now owns 21,500 shares of the biotechnology company’s stock valued at $905,000 after buying an additional 4,100 shares during the last quarter. 78.38% of the stock is currently owned by hedge funds and other institutional investors.

In related news, insider Anastasios Gianakakos sold 3,000 shares of the stock in a transaction that occurred on Thursday, December 21st. The stock was sold at an average price of $41.09, for a total value of $123,270.00. Following the transaction, the insider now owns 512,117 shares of the company’s stock, valued at $21,042,887.53. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Kevin P. Starr sold 816,326 shares of the stock in a transaction that occurred on Wednesday, January 3rd. The stock was sold at an average price of $42.00, for a total value of $34,285,692.00. The disclosure for this sale can be found here. In the last three months, insiders sold 840,326 shares of company stock worth $35,376,662. 33.40% of the stock is owned by insiders.

MYOK has been the topic of a number of analyst reports. BidaskClub raised Myokardia from a “sell” rating to a “hold” rating in a research note on Tuesday, December 12th. TheStreet cut Myokardia from a “c” rating to a “d+” rating in a research note on Friday, November 3rd. Credit Suisse Group reaffirmed an “outperform” rating and set a $60.00 target price on shares of Myokardia in a research note on Thursday, January 18th. JPMorgan Chase & Co. initiated coverage on Myokardia in a research note on Tuesday, December 12th. They set an “overweight” rating and a $54.00 target price on the stock. Finally, Zacks Investment Research cut Myokardia from a “hold” rating to a “sell” rating in a research note on Wednesday, January 3rd. One investment analyst has rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the company. Myokardia currently has a consensus rating of “Buy” and a consensus target price of $55.67.

Myokardia Inc (NASDAQ:MYOK) opened at $55.00 on Wednesday. Myokardia Inc has a 52 week low of $10.80 and a 52 week high of $57.55.

ILLEGAL ACTIVITY NOTICE: “Chartwell Investment Partners LLC Has $1.28 Million Stake in Myokardia Inc (MYOK)” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/02/21/chartwell-investment-partners-llc-has-1-28-million-stake-in-myokardia-inc-myok.html.

About Myokardia

MyoKardia, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics.

Want to see what other hedge funds are holding MYOK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Myokardia Inc (NASDAQ:MYOK).

Institutional Ownership by Quarter for Myokardia (NASDAQ:MYOK)

Receive News & Ratings for Myokardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myokardia and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply